Cardiff Oncology Inc.

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types. The company’s current clinical programs center on difficult-to-treat solid tumors and hematologic malignancies, including colorectal cancer, prostate cancer, pancreatic cancer, lung cancer, and breast cancer. Cardiff Oncology’s work is aimed at addressing treatment resistance and improving the effectiveness of existing cancer regimens through combination approaches. Headquartered in San Diego, California, Cardiff Oncology operates as a focused oncology drug development company within the broader biotechnology sector.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Mani Mohindru Ph.D.

Employees

30

Headquarters

San Diego, CA, United States

Website

www.cardiffoncology.com